Patricia Romero
Family · San Diego, CANPI 1427584226
Payments from drug & device makers
Across 94 payments — averaging $34.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$599
- Novo Nordisk$511
- Bayer$438
- Medtronic$327
- Tandem Diabetes Care, Inc.$165
- Lilly USA, LLC$161
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,210100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $599 |
| Novo Nordisk | 11 | $511 |
| Bayer | 7 | $438 |
| Medtronic | 16 | $327 |
| Tandem Diabetes Care, Inc. | 3 | $165 |
| Lilly USA, LLC | 9 | $161 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $145 |
| Amgen | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Xeris Pharmaceuticals, Inc. | 7 | $113 |
| Dexcom, Inc. | 2 | $110 |
| Johnson & Johnson | 5 | $85 |
| AbbVie | 3 | $62 |
| Astellas Pharma US Inc | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Corcept Therapeutics | 2 | $34 |
| Kaleo, Inc. | 1 | $34 |
| Merck | 1 | $25 |
| Novartis | 1 | $24 |
| Sumitomo Pharma America, Inc. | 2 | $21 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$379
- AIRSUPRA$133
- INJECTAFER$125
- Ozempic$125
- Repatha$125
- RYBELSUS$125
- BREZTRI$119
- t:slim X2 Insulin Pump with Control-IQ$119
How this compares
$3,210 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 240 | $266,845 |
| JardianceEmpagliflozin | 130 | $106,946 |
| FarxigaDapagliflozin Propanediol | 122 | $80,515 |
| RybelsusSemaglutide | 77 | $79,735 |
| VascepaIcosapent Ethyl | 122 | $56,830 |
| KerendiaFinerenone | 73 | $48,661 |
| TrulicityDulaglutide | 35 | $45,451 |
| GemtesaVibegron | 52 | $30,173 |
| TradjentaLinagliptin | 41 | $29,280 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $26,847 |
| JanuviaSitagliptin Phosphate | 30 | $26,800 |
| LinzessLinaclotide | 27 | $19,601 |
| Icosapent Ethyl | 91 | $19,223 |
| EliquisApixaban | 30 | $18,410 |
| EntrestoSacubitril/Valsartan | 25 | $17,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $511 | $346,580317 claims |
| AstraZenecaFarxiga | $599 | $80,515122 claims |
| BayerKerendia | $438 | $48,66173 claims |
| Lilly USA, LLCTrulicity | $161 | $45,45135 claims |
| MerckJanuvia, Janumet, Steglatro | $25 | $44,40267 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $21 | $30,17352 claims |
| AbbVieLinzess | $62 | $19,60127 claims |
| NovartisEntresto | $24 | $17,46025 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $145 | $12,80418 claims |
| Johnson & JohnsonXarelto | $85 | $11,71020 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $45 | $10,54714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in San Diego
- Nancy GardettoSan Diego$394K
- Dawn MeyerSan Diego$270K
- Erin DwyerSan Diego$189K
- Lizaveta NikitsinaSan Diego$36K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.